Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

The following is a summary of “Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Dupilumab improved exacerbations and lung function in patients with COPD and T2 inflammation, regardless of baseline BODE index score.

The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, ...

Netherlands: A recent real-world, long-term study from the BioDay Registry has highlighted a significant incidence of ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely ...

in Japan has granted marketing and manufacturing authorization for Dupixent ® (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in adults whose disease is not ...